SRC Dependent EGFRvIII-STAT5 Activation Drives Resistance of Glioblastoma Cells

Description

Glioblastoma (GBM) is the most lethal primary brain tumor in adults with a less than 5% chance of survival beyond 5 years. With few effective therapies beyond the standard of care, there are often treatment resistant recurrences seen in most

Glioblastoma (GBM) is the most lethal primary brain tumor in adults with a less than 5% chance of survival beyond 5 years. With few effective therapies beyond the standard of care, there are often treatment resistant recurrences seen in most patients. STAT5 is a protein that has shown to be upregulated in highly invasive and treatment resistant GBM. Elucidating the role of STAT5 in GBM could reveal a node of therapeutic vulnerability in primary and recurrent GBM.

Downloads

One or more components are restricted to ASU affiliates. Please sign in to view the rest.
Restrictions Statement

Barrett Honors College theses and creative projects are restricted to ASU community members.

Details

Contributors
Date Created
2022-05
Embargo Release Date
Resource Type
Additional Information
Series
  • Academic Year 2021-2022